Search

To improve understanding of real-world asthma treatment and inform physician education, we evaluated regional variation in asthma prevalence and oral corticosteroid (OCS) use across Germany. We developed a machine learning gradient boosted tree model with IMS® Disease Analyzer electronic medical records, which cover 3% of German patients. This model had a 91% accuracy in predicting the presence of asthma and chronic obstructive pulmonary disease. We applied the model to the IMS® Longitudinal Prescription database, with 82% national coverage, to classify patients receiving treatment for airflow obstruction from October 2017–September 2018 in 63 regions in Germany. Of 2.4 million individuals under statutory health insurance with predicted high OCS use for asthma (defined as 1 tablet per day for the duration of therapy), 13.7%, 18.7%, 36.5%, 29.4%, and 1.7% were categorised as receiving Global Initiative for Asthma (GINA) Steps 1, 2, 3, 4, and 5 treatment, respectively. Approximately 7–15% of those receiving GINA Steps 1–4 treatment, and 35% of those receiving Step 5 treatment received ≥1 acute OCS prescription (duration

Introduction Patients with asthma typically increase short-acting β2-agonists (SABA) use with worsening symptoms. Excessive SABA use may lead to a higher risk of adverse outcomes. We evaluated, in a large population cohort, an association between SABA inhaler use and asthma exacerbations and healthcare utilization. Methods As part of the SABINA (SABA use IN Asthma) global program, we conducted a retrospective longitudinal observational study (SABINA I) using UK primary care electronic healthcare records (Clinical Practice Research Datalink; 2007–2017) from asthma patients aged ≥ 12 years. SABA inhaler use was classified as ‘high use ’ 3 canisters/year versus ‘low use’, 0–2 canisters/year. Taking into consideration all their asthma prescriptions, patients were categorized into a treatment step according to 2016 British Thoracic Society (BTS) asthma management guidelines. Multivariable regression assessed the association of SABA inhaler use by BTS treatment steps (grouped as BTS steps 1/2 and 3–5), separately, and with outcomes of exacerbations or asthma-related healthcare utilization (primary care and hospital outpatient consultations); only patients with linked hospital data were included in this analysis. Results Of the 574,913 patients included, 218,365 (38%) had high SABA inhaler use. Overall, 336,412 patients had linked hospital data. High SABA inhaler use was significantly associated with an increased risk of exacerbations [adjusted hazard ratio, 95% confidence interval (CI): BTS steps 1/2 = 1.20, 1.16–1.24; BTS steps 3–5 = 1.24, 1.20–1.28], asthma-related primary care consultations [adjusted incidence rate ratio (IRR), 95% CI: BTS steps 1/2 = 1.24, 1.23–1.26; BTS steps 3–5 = 1.13, 1.11–1.15), and asthma-related hospital outpatient consultations (adjusted IRR, 95% CI: BTS steps 1/2 = 1.19, 1.12–1.27; BTS steps 3–5 = 1.19, 1.13–1.26). Conclusion High SABA inhaler use was frequent across BTS steps and was associated with a significant increase in exacerbations and asthma-related healthcare utilization.

Introduction Globally, individuals with asthma tend to overrely on short-acting β2-agonists (SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying inflammation. Such relief-seeking behavior has been reinforced by long-standing treatment guidelines, which until recently recommended SABA-only use for immediate symptom relief. We aimed to describe the current burden of SABA use among European individuals with asthma within the SABA use IN Asthma (SABINA) program. Methods Prescription and/or dispensing data during 2006–2017 from electronic medical records and/or national patient registries in the United Kingdom (UK), Germany, Italy, Spain, and Sweden were analyzed. Individuals aged at least 12 years old with a current asthma diagnosis and no other chronic respiratory conditions were included. Asthma treatment step and severity were based on treatment guidelines in use in each individual country. The proportion of individuals prescribed SABA was measured during a 12-month period. SABA overuse was defined as at least three SABA canisters per year. Results More than one million individuals with asthma were included across five European countries. Overall, the majority of individuals were over 45 years of age, except in Sweden (mean age 27.6 years) where individuals aged over 45 years were excluded to avoid a potential chronic obstructive pulmonary disease co-diagnosis. The study population was predominantly female (55–64%), except in the UK (46%). The prevalence of SABA overuse was 9% in Italy, 16% in Germany, 29% in Spain, 30% in Sweden, and 38% in the UK. In the UK, SABA overuse was greater in individuals with moderate-to-severe asthma versus individuals with mild asthma (58% versus 27%, respectively), while SABA overuse was similar in individuals with both mild (9–32%) and moderate-to-severe (8–31%) asthma in the other European countries. Conclusions The findings of this study from the SABINA program show that SABA overuse (at least three canisters per year) is common across Europe, despite the different healthcare and reimbursement policies of each country.

Oral corticosteroids (OCS) are used to manage asthma exacerbations and severe, uncontrolled asthma, but OCS use is associated with adverse effects. We aimed to describe the patterns of OCS use in the real-world management of patients with asthma in western Europe. We used electronic medical records from databases in France, Germany, Italy and the United Kingdom from July 2011 through February 2018. Patients aged ≥12 years with an asthma diagnosis, at least one non-OCS asthma medication within ±6 months of diagnosis, and available data ≥6 months prior to and ≥90 days after cohort entry were included. High OCS use was defined as OCS ≥450 mg prescribed in a 90-day window during follow-up. Baseline characteristics and OCS use during follow-up were described overall and by OCS use status. Of 702 685 patients with asthma, 14–44% were OCS users and 6–9% were high OCS users at some point during follow-up. Annual prevalence of high OCS use across all countries was ∼3%. High OCS users had a mean of between one and three annual OCS prescriptions, with an average daily OCS dosage of 1.3–2.2 mg. For patients who continued to meet the high-use definition, daily OCS exposure was generally stable at 5.5–7.5 mg for ≥2 years, increasing the risk of adverse effects. Our study demonstrates that OCS use is relatively common across the four studied European countries. Data from this study may provide decisive clinical insights to inform primary care physicians and specialists involved in the management of severe, uncontrolled asthma., This study gives a real-world snapshot of oral corticosteroid (OCS) use in western Europe, by highlighting an opportunity to shift towards corticosteroid-sparing therapies or safer alternatives that mitigate the risk of OCS-associated adverse effects http://bit.ly/3cB8kk8

Introduction and objectives A better understanding of differences in asthma prevalence between regions will inform disease management and treatment. To examine regional variations in prevalence of severe asthma and severe, uncontrolled asthma, we analyzed pharmacy records from the United Kingdom. Methods Data for 4,356,990 patients who received treatment for fixed airflow obstruction during 2018 were extracted from IQVIA’s longitudinal database of UK pharmacy records, which included data for 61% of all UK patients from 46% of pharmacies. Indications for prescriptions were not available. Therefore, patients aged Results We identified >3 million patients with asthma. Severe asthma prevalence was approximately 25% overall and was greatest in the southwest and east of England and in parts of Wales (figure). Prevalence of severe asthma was comparatively less for greater London and other metropolitan areas. Prevalence of severe, uncontrolled asthma was greatest for Northern Ireland. Pharmacy migration, nonadherence to medication, and inability to link patients across pharmacies may have resulted in the underestimation of prescriptions, particularly in urban areas where populations are more likely to be transient. However, a sensitivity analysis that included only patients with 100% ICS coverage (adherent and nontransient) did not reveal any large differences in relative prevalences from the primary analysis. Conclusions Regional patterns of severe asthma and severe, uncontrolled asthma were notably different. For some regions, relatively high prevalence might be explained by small patient numbers. Patients may have received high ICS dosages rather than biologic therapies, based on local access restrictions. Despite data limitations, this first heat map analysis of unmet needs for UK patients with severe asthma provides important tools for the discussion on improving severe asthma care.

Background: Oral corticosteroids (OCS) are often prescribed for treatment of asthma exacerbations, or as part of daily maintenance therapy for patients with severe asthma, although they are associated with adverse effects Aims and Objectives: To describe the patterns of OCS use and characteristics of patients with asthma by OCS use status in Italy. Methods: Electronic medical records from the Longitudinal Patient Database for general practice in Italy from 1/7/11–31/12/17 were used. Included patients were ≥12 years old with ≥1 asthma diagnosis and had data available for ≥183 days before and ≥90 days after cohort entry. Long-term (LT) use was defined as ≥450 mg OCS prescribed in a 90-day period during follow up. Patients were classified by their OCS use: non-user or OCS user (including non-LT and LT). Baseline characteristics and OCS prescription patterns during follow up were described overall and by OCS use. Results: Among the 97,187 study patients, 42.6% were OCS users and 8.7% were LT OCS users at some point during follow up. One-year prevalence of LT OCS use from cohort entry was 3.7%. OCS users, especially LT OCS users, were older, were more likely to be female, be obese, have severe asthma, and have more comorbidities, and were less likely to be active smokers than non-OCS users. The mean annual number of OCS prescriptions was 1.7 for LT users and 0.6 for non-LT users. Mean daily OCS dosage was 1.4 mg for LT users and 0.3 mg for non-LT users. Conclusion: OCS use is relatively common in asthma treatment in Italy, suggesting suboptimal asthma management. OCS therapy should be considered carefully to avoid associated adverse effects.

Background: Characterization of regional variation in asthma treatment across Germany will improve understanding of real-world therapy and inform physician education. Aims and Objectives: We aimed to describe regional variation in asthma prevalence and oral corticosteroid (OCS) use in Germany. Methods: We developed a machine learning gradient boosted tree model, with 91% accuracy in predicting the presence of asthma and COPD, using IMS® Disease Analyzer electronic medical records, which cover 3% of German patients. This model was applied to the IMS Longitudinal Prescription database, with 75% national coverage, to classify patients receiving airflow obstruction treatment from Oct 2017–Sept 2018 in 63 regions. Results: Of 2.4 million patients predicted to have asthma, 13.7%, 18.7%, 36.5%, 29.4%, and 1.7% were categorized as GINA stages 1, 2, 3, 4, and 5, respectively. At least one short-term OCS prescription was received by 7–15% of patients in GINA stages 1–4 and 35% of patients in stage 5. At least one maintenance OCS prescription was received by 1–3% of patients in GINA stages 1–4 and 86% in stage 5. Cumulative OCS dosage and percentage of OCS-treated patients differed substantially across regions (figure). Regions with less maintenance OCS use had greater biologic use. Conclusions: Maintenance and short-term OCS use varied across Germany and were greater than recommended by guidelines across the spectrum of asthma severity.

As SABA overuse is associated with exacerbations and mortality, GINA no longer recommends SABA only as a preferred reliever in asthma. A consistent pattern of high SABA use from the SABINA programme would indicate a global public health issue.http://bit.ly/33XDrlb

Background Some observational studies and randomized controlled trials (RCTs) have suggested an association between abacavir (ABC) use and myocardial infarction (MI), whereas others have not. Methods This pooled analysis of 66 phase II–IV RCTs estimates exposure-adjusted incidence rates (IRs) and relative rates (RRs) of MI and cardiovascular events (CVEs) in participants receiving ABC- and non-ABC-containing combination antiretroviral therapy (cART). The primary analysis of MI included ABC-randomized trials with ≥48-week follow-up. Sensitivity analyses of MI and CVEs included non-ABC-randomized and Results In 66 clinical trials, 13 119 adults (75% male, aged 18–85 years) were on ABC-containing cART and 7350 were not. Exposure-adjusted IR for MI was 1.5 per 1000 person-years (PY; 95% confidence interval [CI], 0.67–3.34) in the ABC-exposed group and 2.18 per 1000 PY (95% CI, 1.09–4.40) in the unexposed group. The IR for CVEs was 2.9 per 1000 PY (95% CI, 2.09–4.02) in the exposed group and 4.69 per 1000 PY (95% CI, 3.40–6.47) in the unexposed group with studies of ≥48 weeks of follow-up, with an RR of 0.62 (95% CI, 0.39–0.98). The inclusion of nonrandomized and shorter-duration trials did not significantly change the RR for MI or coronary artery disease. Conclusions This pooled analysis found comparable IRs for MI and CVEs among ABC-exposed and -unexposed participants, suggesting no increased risk for MI or CVEs following ABC exposure in a clinical trial population. Modifiable risk factors for MI and CVEs should be addressed when prescribing ART.

Background Several observational studies and randomized controlled trials (RCTs) have suggested an association between abacavir (ABC) use and myocardial infarction (MI) but others, including meta-analyses of clinical trial data, have not. Methods This updated meta-analysis estimates exposure-adjusted incidence rate (IR) and relative rate (RR) of MI and coronary artery disease (CAD) in subjects receiving ABC and non ABC-containing combination antiretroviral therapy (cART). Summary data from 52 Phase II-IV RCTs from a previous meta-analysis were combined with aggregate data from 14 new RCTs. Subjects were either randomized to ABC cART vs. other cARTs, or ABC was prescribed as a background medication. Primary analyses included ABC-randomized trials with a follow-up of ≥48 weeks and focused on MI. Secondary analyses included shorter duration trials and non-ABC-randomized trials and estimated IR and RR for both MI and CAD. Results In 66 clinical trials (75% male, aged 18–85 years), 13,119 adults were on ABC-containing cART and 7,350 were not. Exposure-adjusted IR for MI was 1.5 per 1,000 person-years (PY) [95% Confidence Interval (CI) 0.67–3.34] in the ABC-exposed group, and 2.18 per 1,000 PY (95% CI 1.09–4.40) in the unexposed group with a RR of 0.69 (95% CI 0.24–1.98). RR for MI was 0.69 (95% CI 0.24–1.99) with inclusion of shorter duration studies, and 0.83 (95% CI 0.44–1.60) with inclusion of ABC non-randomized studies. The IR for CAD was 2.9 per 1,000 PY (95% CI 2.09–4.02) in the ABC-exposed group and 4.69 per 1,000 PY (95% CI 3.4–6.47) in the unexposed group with studies of ≥48 weeks of follow-up, with a RR of 0.62 (95% CI 0.39–0.98). With inclusion of studies of

Increased body mass index (BMI) is a worldwide health issue. Individual differences in the susceptibility to increased BMI could be related to genes or environment. We performed a systematic review of genetic studies on BMI in pre-adolescence, young adulthood and late adulthood. We searched PubMed and EMBASE with heritability, body mass index, BMI, weight, height, anthropometry and twins as search terms. Studies reporting intra-pair correlations of healthy twin pairs that were raised together were included. This resulted in the inclusion of 8,179 monozygotic (MZ) and 9,977 dizygotic (DZ) twin pairs from twelve published studies in addition to individual participant data for 629 MZ and 594 DZ pairs from four twin registries. Structural equation modelling with intra-pair twin correlations showed that the heritability of BMI remained high over all age categories ranging from 61 % (95 % CI 54-64 %) to 80 % (95 % CI 76-81 %) for male and female subjects combined, while unique environmental influences increased from 14 % (95 % CI 13-15 %) to 40 % (95 % CI 37-43 %) with increasing age. Heritability of BMI remains consistently high over different age categories. Environmental changes over time do not seem to have as big a relative impact on an individual's weight as previously reported, suggesting a mainly genetic influence on variation in BMI over the years. © Springer-Verlag 2012.